Your Health, We Care
The coadministration of Ibrutinib with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations. Increased ibrutinib concentrations may increase the risk of drug-related toxicity.
Dose modifications of Ibrutinib are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors.
Avoid concomitant use of other strong CYP3A inhibitors. Interrupt Ibrutinib if these inhibitors will be used short-term (such as anti-infectives for seven days or less).
Avoid grapefruit and Seville oranges during Ibrutinib treatment, as these contain strong or moderate inhibitors of CYP3A.
The coadministration of Ibrutinib with strong CYP3A inducers may decrease ibrutinib concentrations. Avoid coadministration with strong CYP3A inducers.
from FDA，2024.05
